title: Disease-modifying anti-rheumatic drugs for refractory severe knee synovitis in patients with peripheral spondyloarthritis: efficacy and predictors of response.
abstract: OBJECTIVE
  In this study we aimed to evaluate the efficacy of disease-modifying anti-rheumatic drugs (DMARDs) for severe knee synovitis, refractory to low-dose oral corticosteroids and/or non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular (IA) corticosteroid injections, in patients with peripheral spondyloarthritis (SpA). We also examined the association between the clinical response of knee synovitis and demographic and clinical parameters of the studied patients.
  
  
  METHODS
  Patients with SpA-related arthritis including resistant and severe knee synovitis, defined as the presence of swelling, tenderness, and a decreased range of movement on clinical examination, treated with DMARDs between January 2005 and January 2012 were studied retrospectively. No evidence of knee synovitis was considered a clinical response to DMARDs.
  
  
  RESULTS
  Forty-five patients [mean age 41.0 ± 1.9 years; 33 (73.3%) males] were studied. In 14 (31.1%) of the patients there was a clinical response of knee synovitis, while the remaining 31 (68.9%) patients were non-responders. Response to DMARD therapy was associated with disease subtype (p = 0.011) and HLA-B27 (p = 0.023) but not with a history of psoriasis (p = 0.067) or age at disease onset (p = 0.054). However, only a history of psoriasis could independently predict the response to DMARDs [adjusted odds ratio (OR) 0.232, p = 0.049].
  
  
  CONCLUSIONS
  One-third of the patients with peripheral SpA and severe resistant knee synovitis had a clinical response to DMARD therapy. Disease subtype and HLA-B27 were associated with the response of knee synovitis to DMARDs, but only psoriasis could independently predict this response.
authors.affiliation: Department of Rheumatology, 424 General Military Hospital , Thessaloniki , Greece.
authors.forename: G T
authors.initials: GT
authors.lastname: Sakellariou
authors.forename: F E
authors.initials: FE
authors.lastname: Sayegh
authors.forename: A D
authors.initials: AD
authors.lastname: Anastasilakis
authors.forename: I
authors.initials: I
authors.lastname: Bisbinas
authors.forename: G A
authors.initials: GA
authors.lastname: Kapetanos
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D015796:HLA-B27 Antigen / Q000276:immunology; D006801:Humans; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D016059:Range of Motion, Articular; D012189:Retrospective Studies; D025242:Spondylarthropathies / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013585:Synovitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D015796:HLA-B27 Antigen